AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15163773
Drug: PSA level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA level 0.6 to 1.0 ng/mL
Trial: 15163773
Drug: PSA level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA level 1.1 to 2.0 ng/mL
Trial: 15163773
Drug: PSA level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA level 2.1 to 3.0 ng/mL
Trial: 15163773
Drug: PSA level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA level 3.1 to 4.0 ng/mL
Trial: 11210401
Drug: Sevelamer hydrochloride
RxNorm normalized name: Sevelamer Hydrochloride
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevelamer hydrochloride (2.4 g doses)
Trial: 9596048
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy (n = 27)
Trial: 3135734
Drug: Intravenous nitroprusside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nitroprusside (NTP)
Trial: 29308591
Drug: Intranasal ELI‐200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal ELI‐200 (30‐mg oxycodone hydrochloride/3‐mg naltrexone HCl)
Trial: 29308591
Drug: Intranasal oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal oxycodone immediate release (30‐mg oxycodone HCl)
Trial: 29308591
Drug: Oral ELI‐200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ELI‐200 (30mg/3mg)
Trial: 19198708
Drug: Oral dextromethorphan
RxNorm normalized name: dextromethorphan Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dextromethorphan (45 mg)
Trial: 11372025
Drug: Baseline drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline drug resistance mutations
Trial: 9656393
Drug: Artemether (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether (150 and 100 mg) with mefloquine (750 and 500 mg)
Trial: 9656393
Drug: Artesunate (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artesunate (150 and 100 mg) with mefloquine (750 and 500 mg)
Trial: 3112428
Drug: 91-cm 3.0-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 91-cm 3.0-g weighted tube (Entriflex, Biosearch, Raritan, NJ)
Trial: 27687347
Drug: Neostigmine (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine (0.05 mg/kg) and Atropine (0.01 mg/kg)
Trial: 24742955
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of dietary‐induced weight loss and exercise (D + E; n = 101)
Trial: 22520138
Drug: PRV (pentavalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRV (pentavalent rotavirus vaccine)
Trial: 20019677
Drug: Low-carbohydrate diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-carbohydrate diet (<30 g/day)
Trial: 15810646
Drug: Rifaximin, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin, 200 mg bid (Group R1: 39 pts)
Trial: 15810646
Drug: Rifaximin, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin, 400 mg bid (Group R2: 43 pts)
Trial: 15810646
Drug: Mesalazine, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalazine, 400 mg bid (Group M1: 40 pts)
Trial: 15810646
Drug: Mesalazine, 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalazine, 800 mg bid (Group M2: 48 pts)
Trial: 12375668
Drug: Prophylactic calcium
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic calcium (Ca) chloride or Ca gluconate at a dose linked to citrate infusion rate (1.0‐2.2 mg/kg/min)
Trial: 12375668
Drug: Citrate administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrate administration
Trial: 7842770
Drug: Furosemide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (10 mg/m2 of body)
Trial: 7842770
Drug: Amiloride (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride (0.3 mg/m2 of body)
Trial: 651283
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg lanatosid C in saline
Trial: 31923712
Drug: Whole Pelvic
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole Pelvic Radiation Therapy (WPRT, 68 Gy/25# to prostate and 50 Gy/25# to pelvis)
Trial: 31923712
Drug: Prostate Only
RxNorm normalized name: Sus scrofa prostate preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostate Only Radiation Therapy (PORT, 68 Gy/25# to prostate)
Trial: 31923712
Drug: Prostate Only
RxNorm normalized name: Sus scrofa prostate preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostate Only Radiation Therapy (PORT)
Trial: 31923712
Drug: Whole Pelvic
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole Pelvic Radiation Therapy (WPRT) and Prostate Only Radiation Therapy (PORT)
Trial: 23235363
Drug: telmisartan 80
RxNorm normalized name: telmisartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: telmisartan 80 mg and aliskiren 300 mg
Trial: 23235363
Drug: telmisartan 80
RxNorm normalized name: telmisartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: telmisartan 80 mg and eplerenone 50 mg
Trial: 23235363
Drug: telmisartan 160
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: telmisartan 160 mg as monotherapy
Trial: 16078963
Drug: Newer drugs
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Newer drugs
Trial: 24952730
Drug: Older agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Older agents
Trial: 10025924
Drug: Interferon-alpha (IFNalpha)
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha (IFNalpha) 13.5 x 10(6) units per week in divided doses
Trial: 3902105
Drug: Pimozide 2
RxNorm normalized name: pimozide 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimozide 2 mg or 6 mg
Trial: 3902105
Drug: Thioridazine 25
RxNorm normalized name: thioridazine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thioridazine 25 mg or 75 mg
Trial: 3902105
Drug: Combined administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined administration of pimozide and thioridazine
Trial: 30810462
Drug: Hydrogel bulking
RxNorm normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogel bulking agent (Bulkamid®)
Trial: 30810462
Drug: Collagen gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagen gel (Contigen®)
Trial: 26306566
Drug: Dietary supplement
RxNorm normalized name: dietary supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplement containing β-hydroxy-β-methylbutyrate (HMB), glutamine and arginine (3g HMB, 14g glutamine, 14g arginine daily for 6 months)
Trial: 21352670
Drug: Traditional standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional standard chest physical therapy
Trial: 17725180
Drug: Stavudine 40
RxNorm normalized name: stavudine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stavudine 40 mg capsules (Ranbaxy Laboratories Ltd.)
Trial: 17725180
Drug: Zerit 40
RxNorm normalized name: Zerit 40mg Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zerit 40 mg capsules (Bristol-Myers Squibb)
Trial: 9891830
Drug: Angioplasty with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angioplasty with high Lp (a) levels (above 0.30 g/l)
Trial: 7241682
Drug: Cinoxacin 500
RxNorm normalized name: cinoxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinoxacin 500 mg twice daily for 10 days
Trial: 7241682
Drug: Trimethoprim-sulfamethoxazole 160-800
RxNorm normalized name: sulfamethoxazole
DrugBank: Sulfamethoxazole (DB01015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole 160-800 mg twice daily for 10 days
Trial: 28646784
Drug: 30min of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30min of morning light therapy (5,000lx; blue-enriched polychromatic light, 17,000K)
Trial: 26216608
Drug: Nasal balloon
RxNorm normalized name: CATHETER,BALLOON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal balloon autoinflation 3 times daily for 1-3 months plus usual care
Trial: 22935321
Drug: High blueberry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High blueberry dose (75 g)
Trial: 22935321
Drug: Low blueberry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low blueberry dose (35 g)
Trial: 22935321
Drug: Control (ascorbic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (ascorbic acid and sugar matching high blueberry dose)
Trial: 8141279
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (0.03 mg.kg ideal body wt‐1.day‐1)
Trial: 2183716
Drug: Endotracheal tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Endotracheal tobramycin (40 mg every 8 h)
Trial: 6107407
Drug: Cholecalciferol (vitamin
RxNorm normalized name: cholecalciferol (vitamin D3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol (vitamin D3) 3000 units (75 micrograms) daily
Trial: 6107407
Drug: 1,25-dihydroxycholecalciferol 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,25-dihydroxycholecalciferol 1 microgram daily
Trial: 28152124
Drug: Subretinal injection
RxNorm normalized name: LUXTURNA Suspension for Subretinal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subretinal injection of 0.1 mL of a gene therapy solution containing 1 × 10^11 viral particles
Trial: 23172847
Drug: Lifestyle treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle treatment programme with physiotherapist involvement
Trial: 23172847
Drug: Lifestyle treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle treatment programme without physiotherapist involvement
Trial: 21216670
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg once per day, orally) for 3 months starting 5-10 days after stroke onset
Trial: 17382151
Drug: Lidocaine ointment
RxNorm normalized name: Lidocaine Ointment
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine ointment combined with tramadol drops 1 mg/kg per os 40 minutes before the procedure (group 2)
Trial: 17382151
Drug: 5% lidocaine
RxNorm normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% lidocaine ointment 5 mL per rectum 10 minutes before the procedure (group 1)
Trial: 15245526
Drug: Wet wrap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wet wrap therapy (WWT) with 1% hydrocortisone (HC) applied once in the morning for 2 weeks, wet wraps twice daily for week 1, and only at night for week 2
Trial: 15245526
Drug: Hydrocortisone (HC)
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone (HC) applied twice daily without wet wraps
Trial: 11753990
Drug: Radiotherapy (RT),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy (RT), mean total dose 65 grays (Gy; 62.3-70 Gy)
Trial: 11753990
Drug: Deferred treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred treatment (DT)
Trial: 9669469
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone (IVMP) pulse therapy (2 g)
Trial: 3154322
Drug: Chronic versus
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic versus single digoxin dosing
Trial: 26092311
Drug: Dopamine D2-receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine D2-receptor antagonist sulpiride (400 mg)
Trial: 22752050
Drug: Risedronate 150-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 150-mg once a month
Trial: 22752050
Drug: Risedronate 5-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 5-mg daily
Trial: 20964572
Drug: 2% sunflower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% sunflower oleodistillate (SO) cream applied twice a day
Trial: 20964572
Drug: Hydrocortisone butyro-propionate
RxNorm normalized name: propionate
DrugBank: Propionate ion (DB19384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone butyro-propionate 1 mg/g applied twice a day
Trial: 18164562
Drug: 17beta‐estradiol 1mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17beta‐estradiol 1mg plus norethisterone acetate 0.5 mg (E(2)/NETA)
Trial: 18164562
Drug: raloxifene HCl
RxNorm normalized name: raloxifene HCl
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: raloxifene HCl 60 mg
Trial: 16418760
Drug: Gx (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gx (500 mg capsules containing 6 mg synephrine, 150 mg caffeine, and 150 mg catechin polyphenols)
Trial: 14593356
Drug: Ticlopidine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine (500 mg BID loading dose for 2 days and 250 mg BID for subsequent 5 days)
Trial: 14593356
Drug: Clopidogrel (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300 mg loading dose and 75 mg/day for subsequent 6 days)
Trial: 11001866
Drug: 30 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/day prednisolone
Trial: 6389477
Drug: Enoxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxacin (400 mg twice daily for 14 days)
Trial: 12131781
Drug: Loxiglumide 300
RxNorm normalized name: Dexloxiglumide
DrugBank: Dexloxiglumide (DB04856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loxiglumide 300 mg/d
Trial: 12131781
Drug: Loxiglumide 600
RxNorm normalized name: Dexloxiglumide
DrugBank: Dexloxiglumide (DB04856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loxiglumide 600 mg/d
Trial: 12131781
Drug: Loxiglumide 1200
RxNorm normalized name: Dexloxiglumide
DrugBank: Dexloxiglumide (DB04856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loxiglumide 1200 mg/d
Trial: 10220845
Drug: Supervised physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised physical therapy rehabilitation (1 h, twice weekly) with emphasis on balance training
Trial: 10220845
Drug: Supervised physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised physical therapy rehabilitation
Trial: 7823670
Drug: Face-washing intervention
RxNorm normalized name: Phisoderm Clear Confidence Daily Gel Face Wash
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face-washing intervention program plus mass topical antibiotic treatment
Trial: 7823670
Drug: Mass topical
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass topical antibiotic treatment only (Control)
Trial: 31309627
Drug: Topical product
RxNorm normalized name: Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical product containing 3 antioxidants (pre‐tocopheryl®, retinaldehyde, glycylglycine ole‐amide)
Trial: 31309627
Drug: Positive antioxidant
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive antioxidant control cream
Trial: 28412590
Drug: Ramucirumab treatment
RxNorm normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ramucirumab treatment for CEA ≤10 subgroup
Trial: 28412590
Drug: Ramucirumab treatment
RxNorm normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ramucirumab treatment for CEA >10 subgroup
Trial: 28412590
Drug: Ramucirumab treatment
RxNorm normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ramucirumab treatment
Trial: 25468160
Drug: Obeticholic acid
RxNorm normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Obeticholic acid (25 mg daily for 72 weeks)
Trial: 23245591
Drug: Meperidine (0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine (0.7 mg/kg) with sham patient controlled analgesia (Group M)
Trial: 23245591
Drug: Remifentanil 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 0.5 μg/kg with patient-controlled analgesia pump (Group R1)
Trial: 23245591
Drug: Remifentanil 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 0.8 μg/kg with patient-controlled analgesia pump (Group R2)
Trial: 21460373
Drug: Isoniazid (INH)
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid (INH) combined with Antiretroviral therapy (ART)
Trial: 17522096
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (exercise and manipulation)
Trial: 9543282
Drug: inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhaled corticosteroids
Trial: 9543282
Drug: oral corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral corticosteroids
Trial: 8297217
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg IV DMT
Trial: 8297217
Drug: 0.4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg/kg IV DMT
Trial: 8297217
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg IV DMT
Trial: 8297217
Drug: 0.05 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg/kg IV DMT
Trial: 4357135
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate 400 mug daily
Trial: 26294143
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (antibiotics at physician's discretion)
Trial: 17727576
Drug: Behavioural modification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioural modification (moderation of fluid intake or timing of taking anti-diuretic medication)
Trial: 17727576
Drug: Antimuscarinic agents
RxNorm normalized name: ANTIMUSCARINICS/ANTISPASMODICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimuscarinic agents or desmopressin (a nona-peptide analogue of anti-diuretic hormone)
Trial: 10867212
Drug: Heparin-induced extracorporeal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-induced extracorporeal LDL/fibrinogen precipitation (HELP)
Trial: 9100583
Drug: Thyroxine dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroxine dose changes
Trial: 7691426
Drug: Aprotinin 1
RxNorm normalized name: aprotinin 1.4 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin 1 million KIU (200,000 KIU bolus followed by 100,000 KIU/hr infusion for 8 hours)
Trial: 20144858
Drug: Long-term humidification
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term humidification therapy
Trial: 18564957
Drug: Directly applied
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Directly applied mud pack treatment (heated mud, up to 43 degrees C, applied directly for 30 minutes, 15 applications)
Trial: 18564957
Drug: Nylon-covered mud
RxNorm normalized name: NYLON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nylon-covered mud pack treatment (same treatment as study group but with nylon cover)
Trial: 9884381
Drug: Epinephrine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine (10 micromol/L)
Trial: 9884381
Drug: Zinterol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinterol (10 micromol/L)
Trial: 9884381
Drug: Norepinephrine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine (10 micromol/L)
Trial: 1884968
Drug: 1:10000 adrenalin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1:10000 adrenalin injection
Trial: 1884968
Drug: 1:10000 adrenalin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1:10000 adrenalin +1% aethoxysclerol injection
Trial: 22253296
Drug: 1,000 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg/d of elemental calcium carbonate plus 400 IU/d of vitamin D(3)
Trial: 20598973
Drug: Intracoronary administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary administration of autologous bone marrow mononucleated cells (BM‐MNCs) at 5 to 7 days after AMI
Trial: 20598973
Drug: Intracoronary administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary administration of autologous bone marrow mononucleated cells (BM‐MNCs) at 3 to 4 weeks after AMI
Trial: 15613506
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation (3 mg/kg/day) in the iron supplemented (IS) group; n = 37
Trial: 10536353
Drug: Conventional smear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional smear (CS) preparation